CSPC Pharmaceutical Group (HKG:1093) said the biologic license application for the ustekinumab injection has been accepted by China's National Medical Products Administration, a Tuesday bourse filing said.
The ustekinumab injection has been developed by CSPC Megalith Biopharmaceutical, a unit of the pharmaceutical company said.
The injection is a therapeutic biological product for the indication of plaque psoriasis in adults and children.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.